Login
Navigate Fool.com
Will PTCT beat
the market?

PTC Therapeutics, Inc.

NASDAQ: PTCT

Community Rating: 1 Star: Ominous

18.78 -0.99 (-5.01%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $19.62
Previous Close $19.77
Daily Range $18.58 - $20.26
52-Week Range $13.04 - $34.65
Market Cap $564.8M
P/E Ratio -3.63
Dividend (Yield) $0.00 (0.0%)
Volume 131,260
Average Daily Volume 297,336
Current FY EPS -$2.59

How do you think PTCT
will perform against the market?

Top PTCT Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

Why PTC Therapeutics, Inc. Shares Dipped

PTC Therapeutics shares sink after it reports its fourth-quarter results. Here what shareholders should really be focused on instead.

Wednesday's ETF Movers: GDXJ, XBI

Friday Sector Laggards: Drugs, Biotechnology Stocks

Companies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?

2014 starts a dismal year for Duchenne prospects by Sarepta, Prosensa, PTC and Retrophin

This Week in Biotech: An FDA and CHMP Smackdown Ensues

A quartet of rejections from regulatory bodies overshadows the lone bright spot in Part 1 of This Week in Biotech.

Why PTC Therapeutics Shares Temporarily Sank

PTC Therapeutics shares stumbled out of the gate following a European advisory panel opinion, but quickly regained their poise.

3 Humongous Health-Care Stocks This Week

Therapeutics ruled the world of health-care this week -- with Chelsea, PTC, and Stemline coming out on top and Sarepta and Cell not far behind.

Finding Very Valuable Patients

Sarepta, BioMarin, and Sanofi are doing a good job; Prosensa, GlaxoSmithKline and PTC Therapeutics should take note.

Meet the 2 Newest Investments in Cystic Fibrosis

Investors can now invest in two new companies eyeing the orphan disease. Are they worth it?

Will 1 Biotech's Pain Be Another's Long-Term Gain?

Does the failure of GlaxoSmithKline and Prosensa’s DMD treatment spell instant success for primary competitor Sarepta Therapeutics?

See More PTCT News...

Sector

Industry

PTC Therapeutics, Inc. (PTCT) Description

PTC Therapeutics, Inc. Website: http://www.ptcbio.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks